Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Eledon’s tegoprubart plays key role in recent GM pig kidney transplant

Eledon Pharmaceuticals (NASDAQ:ELDN) has announced that its investigational anti-CD40L antibody, tegoprubart, was used as a key component of the immunosuppression therapy regimen in a patient who recently received a...

February 11, 2025

Developments

OIO grants HEALWELL regulatory approval to acquire Orion Health

HEALWELL AI (TSX:AIDX; QTCQX:HWAIF) has announced that New Zealand’s Overseas Investment Office (OIO) has granted consent for the company to acquire all ordinary shares of Orion Health, based in Auckland, New Zealand...

February 10, 2025

Developments

Medincell reports completion of Phase 3 trial of olanzapine LAI in schizophrenia

Medincell (EPA:MEDCL) has announced the completion of SOLARIS, its Phase 3 trial of olanzapine LAI in patients with schizophrenia, conducted by Teva Pharmaceuticals (NYSE:TEVA). Medicell reports that it will receive a...

February 10, 2025

Developments

FDA fast tracks Biodexa’s eRapa in FAP

Biodexa Pharmaceuticals (NASDAQ:BDRX) has announced that eRapa, a form of rapamycin being developed for the treatment of familial adenomatous polyposis (FAP), has been granted Fast Track Designation by the FDA...

February 10, 2025

Developments

Ekso Bionics names National Seating & Mobility as exclusive distributor of Ekso Indego Personal device within the complex rehabilitation technology industry

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) has named National Seating & Mobility (NSM), a leading provider of complex rehabilitation technology (CRT), mobility and accessibility solutions, as the exclusive Ekso...

February 10, 2025

Developments

New data from BioRestorative Therapies’ ongoing Phase 2 trial of cell-based BRTX-100 in cLDD potentially show disc microenvironment remodeling in addition to reported improvements in VAS and ODI

BioRestorative Therapies (NASDAQ:BRTX) presented new preliminary 26–52 week blinded data from the first 15 patients with chronic lumbar disc disease (cLDD) enrolled in the ongoing Phase 2 clinical trial of BRTX-100. The...

February 10, 2025

Developments

Firefly congratulates company advisor, Dr. Christopher Wilson, on UW Faculty of Engineering Award for his work on superconducting quantum electronics

Firefly Neuroscience (NASDAQ:AIFF) has announced that Christopher Wilson, Ph.D., has been honored with the prestigious UW Faculty of Engineering Award by the University of Waterloo (UW) for his significant contributions...

February 7, 2025

Developments

Fennec unveils PEDMARQSI in Germany for cisplatin-induced hearing loss in children

Fennec Pharmaceuticals (NASDAQ:FENC; TSX:FRX) announced the commercial launch of PEDMARQSI sodium thiosulfate injection in Germany by Norgine Pharmaceuticals. The treatment is designed to prevent ototoxicity (permanent...

February 7, 2025

Developments

AIM addresses avian flu with follow-up clinical study of Ampligen and FluMist combo

AIM ImmunoTech (NYSE:AIM) has announced plans for a follow-up clinical study to evaluate the potential avian influenza combination therapy of its Ampligen with Astra Zeneca’s (NASDAQ: AZN) FluMist. According to AIM, the...

February 7, 2025

Developments

Lively X discussion about the clinical potential of Perimeter’s AI-driven, wide field OCT margin visualization technology during breast cancer surgeries helps drive stock

Perimeter Medical Imaging AI’s (TSX-V:PINK; OTC:PYNKF) ultra-high-res imaging tool for use during breast cancer surgeries was highlighted in a conversation today on X driven by renowned Silicon Valley venture...

February 4, 2025

Developments

Pyxis initiates new combination trial; expands existing monotherapy trial

Pyxis Oncology (NASDAQ:PYXS) has announced the initiation of a Phase 1/2 combination trial of its PYX-201 in conjunction with Merk’s (NYSE: MRK) anti-PD-1 therapy, KEYTRUDA (pembrolizumab), for the treatment of multiple...

February 4, 2025

Developments

uniQure completes enrollment for Phase 1/2a trial of gene therapy in Fabry disease

uniQure (NASDAQ:QURE) has announced the completion of enrollment for its Phase 1/2a trial of AMT-191 in patients with Fabry disease. The company also reports receiving a favorable recommendation from the Independent...

February 3, 2025

Developments

Vanda and Anaptys ink licencing agreement for commercialization of imsidolimab in GPP

Vanda Pharmaceuticals (NASDAQ:VNDA) and AnaptysBio (NASDAQ: ANAB) have announced an exclusive global licencing agreement granting Vanda the rights to commercialize imsidolimab, a treatment for generalized pustular...

February 3, 2025

Developments

Fractyl increases focus on key gene therapy programs

Fractyl Health (NASDAQ:GUTS) has announced plans to prioritize its REMAIN-1 pivotal study, advance its novel Rejuva gene therapy platform into first-in-human studies, and pause investment in its Revita programs for Type...

January 31, 2025

Developments

INBS upgrades portable drug screening reader with multilingual capabilities

Intelligent Bio Solutions (INBS) (NASDAQ:INBS) has announced plans to upgrade its drug screening reader, the Intelligent Fingerprinting Drug Screening System, to support multiple languages across North and South...

January 31, 2025

Developments

HeartBeam files 510(k) application with FDA for ECG software

HeartBeam (NASDAQ:BEAT) has announced the submission of a 510(K) application to the FDA for its 12-lead electrocardiogram (ECG) synthesis software, designed to analyze diverse cardiac rhythms and arrhythmias, leveraging...

January 30, 2025

Developments

HOOKIPA completes enrollment in Phase 1b study of HB-500 in HIV

HOOKIPA Pharma (NASDAQ:HOOK) has announced the completion of enrollment for its Phase 1b trial evaluating HB-500 in patients with HIV. The company stated that the study is comprised of two dose-escalation cohorts, with...

January 30, 2025

Developments

Tectonic announces positive Phase 1b results for TX45 in HFpEF

Tectonic Therapeutic (NASDAQ:TECX) has announced positive interim data from its Phase 1b acute hemodynamic clinical trial of TX45 in Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH...

January 30, 2025

Developments

Polyrizon files patent application with ILPO for T&T technology

Polyrizon (NASDAQ:PLRZ) has announced the filing of a patent application for its advanced intranasal drug delivery system Trap & Target (T&T) technology, with the Israel Patent Office (ILPO). The company stated...

January 30, 2025

Developments

Model Medicines unveils AI-driven pipeline breakthrough; demonstrates end-to-end drug discovery capabilities

Closely held Model Medicines has announced the unveiling of a generative AI-driven, multi-modal therapeutic pipeline breakthrough, showcasing its end-to-end drug discovery capabilities for novel target discovery...

January 28, 2025

Developments

NLS launches preclinical program for Mazindol ER in fentanyl addiction

NLS Pharmaceutics (NASDAQ:NLSP; NASDAQ:NLSPW) has announced the launch of a preclinical program to evaluate Mazindol ER as a novel treatment for fentanyl dependence. According to the Centers for Disease Control and...

January 28, 2025

Developments

Conduit partners with Sarborg to advance drug development with AI

Conduit Pharmaceuticals (NASDAQ:CDT) has announced that the first phase in its collaboration with Sarborg, aimed at integrating advanced AI and cybernetics technology into its operations has been completed. The company...

January 28, 2025

Subscribe